Evidence

Evidence beyond compare

In an assessment conducted by the National Institute for Health and Care Excellence (NICE) evaluating the quality of data for dermal substitute studies in diabetic foot ulcers, GRAFIX Cryopreserved Placental Membrane had the highest overall effect and was the only dermal substitute determined to have high quality of evidence with no serious risk of bias.2-4


62% of DFUs (n=97) closed with GRAFIX Membrane at 12 weeks vs. 21% with standard of care alone (p=0.0001)24,25

See the study

59% of complex DFUs (n=27) closed with GRAFIX Membrane at 16 weeks26

See the study

53% of VLUs that failed to close with 12 weeks SOC went on to close with GRAFIX Membrane + standard of care (p<0.001)27

See the study

59% of DFUs (n=350) closed with GRAFIX Membrane30

See the study

76% of chronic wounds (n=67) closed with GRAFIX Membrane at 12 weeks34

See the study

59% of chronic wounds (n=98) achieved complete wound closure with GRAFIX PL Membrane28

See the study

63% of chronic wounds (n=40) closed with GRAFIX Membrane29

18% of chronic wounds (n=39) closed with EpiFix™ (p<0.0001)29

See the study

For DFUs ≤5 cm2, significantly more patients achieved complete wound closure with GRAFIX PRIME Membrane compared with Dermagraft®36

See the study

A closer look at the use of Placental Membranes for wound closure

Read the white paper

View a summary of this clinical evidence here.